CD8A and neoplasm: Our data also indicate a superior antitumor effect of iExoSTINGa treatment compared with STINGa, and the reduced tumor growth with iExoSTINGa was associated with an influx of proliferating CD8+ T cells, in agreement with previous studies reporting antitumor response with STING pathway activation (4, 35).